Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA-A CANCER J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535–554. doi:10.1016/S0140-6736(21)00312-3
   PubMed Web of Science ®Google Scholar
• Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506–518. doi:10.21037/tlcr.2020.03.40
   PubMed Web of Science ®Google Scholar
• Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol. 2007;2(8):735–740. doi:10.1097/JTO.0b013e31811f3a7d
   PubMed Web of Science ®Google Scholar
• Spini A, Gini R, Rosellini P, et al. First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: a real-life setting study with gender prospective. Cancers. 2021;13:23. doi:10.3390/cancers13236129
   Web of Science ®Google Scholar
• Lai C-L, Wei Y-F, Hsia T-C, et al. S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan. Asia Pac J Clin Oncol. 2020;16(2):e68–73. doi:10.1111/ajco.13294
   PubMed Web of Science ®Google Scholar
• Daly ME, Singh N, Ismaila N, et al. Management of stage III non–small-cell lung cancer: ASCO guideline. J Clin Oncol. 2021;40(12):1356–1384. doi:10.1200/JCO.21.02528
   PubMed Web of Science ®Google Scholar
• Icard P, Schussler O, Loi M, et al. Pre-disease and pre-surgery BMI, weight loss and sarcopenia impact survival of resected lung cancer independently of tumor stage. Cancers. 2020;12(2):Feb. doi:10.3390/cancers12020266
   Web of Science ®Google Scholar
• Shepshelovich D, Xu W, Lu L, et al. Body Mass Index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: a pooled analysis of the international lung cancer consortium. J Thorac Oncol. 2019;14(9):1594–1607. doi:10.1016/j.jtho.2019.05.031
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu Y, Shao H, Zheng X. Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications. J Thorac Oncol off Publ Int Assoc Study Lung Cancer. 2017;12(10):1478–1488.
   Google Scholar
• Petrelli F, Cortellini A, Indini A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e213520–e213520. doi:10.1001/jamanetworkopen.2021.3520
   PubMed Web of Science ®Google Scholar
• Yuan QY, Du ML, Loehrer E, et al. Postdiagnosis BMI change is associated with non-small cell lung cancer survival. CANCER Epidemiol BIOMARKERS Prev. 2022;31(1):262–268. doi:10.1158/1055-9965.EPI-21-0503
   PubMed Web of Science ®Google Scholar
• You D, Wang D, Wu Y, et al. Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study. BMC Med. 2022;20:1. doi:10.1186/s12916-022-02400-6
   PubMed Web of Science ®Google Scholar
• Simmons CP, Koinis F, Fallon MT, et al. Prognosis in advanced lung cancer – a prospective study examining key clinicopathological factors. Lung Cancer. 2015;88(3):304–309. doi:10.1016/j.lungcan.2015.03.020
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(4):504–535. doi:10.6004/jnccn.2017.0050
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Sok M, Zavrl M, Greif B, Srpčič M. Objective assessment of WHO/ECOG performance status. Support Care Cancer off J Multinatl Assoc. 2019;27(10):3793–3798.
   PubMed Web of Science ®Google Scholar
• Ma M, Cao R, Wang W, et al. The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and meta-analysis. J Cardiothorac Surg. 2021;16(1):243. doi:10.1186/s13019-021-01618-4
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.081
   PubMed Web of Science ®Google Scholar
• Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;(2):122–133. doi:10.3978/j.issn.2072-1439.2010.12.08
   PubMed Web of Science ®Google Scholar
• Kubota K, Sakai H, Katakami N, et al. A randomized Phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol off J Eur Soc Med Oncol. 2015;26(7):1401–1408. doi:10.1093/annonc/mdv190
   PubMed Web of Science ®Google Scholar
• Hildebrandt MAT, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009;5(7):745–755. doi:10.1517/17425250902973711
   PubMed Web of Science ®Google Scholar
• Yin J-Y, Huang Q, Zhao Y-C, Zhou -H-H, Liu Z-Q. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One. 2012;7(6):e38150. doi:10.1371/journal.pone.0038150
   PubMed Web of Science ®Google Scholar
• Radkiewicz C, Dickman PW, Johansson ALV, Wagenius G, Edgren G, Lambe M. Sex and survival in non-small cell lung cancer: a nationwide cohort study. PLoS One. 2019;14(6):e0219206. doi:10.1371/journal.pone.0219206
   PubMed Web of Science ®Google Scholar
• Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol. 2007;33(6):763–768. doi:10.1016/j.ejso.2007.01.001
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Schiller JH, Bonomi PB, et al.Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on eastern cooperative oncology group clinical trials. J Thorac Oncol. 2013;(9):1121–1127. doi:10.1097/JTO.0b013e31829cf942
   PubMed Web of Science ®Google Scholar
• Hua H, Kong Q, Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J Hematol Oncol. 2020;13(1):64. doi:10.1186/s13045-020-00904-3
   PubMed Web of Science ®Google Scholar
• Hall RG, Jean GW, Sigler M, Shah S. Dosing considerations for obese patients receiving cancer chemotherapeutic agents. Ann Pharmacother. 2013;47(12):1666–1674. doi:10.1177/1060028013509789
   PubMed Web of Science ®Google Scholar
• Lashinger L, Rossi E, Hursting S. Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation. Clin Pharmacol Ther. 2014;96:458–463. doi:10.1038/clpt.2014.136
   PubMed Web of Science ®Google Scholar
• Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Prim. 2018;4:17105. doi:10.1038/nrdp.2017.105
   PubMed Web of Science ®Google Scholar